Despite promising clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from PBMs. The organizations are often erecting barriers https://haseebxfod131890.blogofchange.com/42696677/the-vyndamax-faces-is-dealing-with-managed-care-organization-hurdles-the-look-at-access-disputes